A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke

European Journal of Neurology

Volumn 13, Issue 10, 2006, Pages 1106-1111

  Mikulik R ^a,b   Dufek, M ^a   Goldemund, D ^a   Reif, M ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulants; Low molecular weight heparin; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANKIN SCALE; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33748930443     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01458.x     Document Type: Article

References (27)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 1995; 333: 1581-1587.
2. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
3. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 862-867.
4. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Annals of Neurology 1992; 32: 78-86.
5. Rother J, Schellinger PD, Gass A, et al. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke 2002; 33: 2438-2445.
6. Nighoghossian N, Hermier M, Adeleine P, et al. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke 2003; 34: 458-463.
7. Christou I, Burgin WS, Alexandrov AV, Grotta JC. Arterial status after intravenous TPA therapy for ischaemic stroke. A need for further interventions. International Angiology 2001; 20: 208-213.
8. Alexandrov AV, Demchuk AM, Felberg RA, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. Stroke 2000; 31: 610-614.
9. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001; 32: 89-93.
10. Burke SE, Lubbers NL, Nelson RA, Henkin J. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model. Thrombosis and Haemostasis 1993; 69: 375-380.
11. Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarctionISIS-3 . Lancet 1992; 339: 753-770.
12. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England Journal of Medicine1993; 329: 673-682.
13. Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. Journal of the American College of Cardiology 1992; 20: 31-35.
14. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25: 2220-2226.
15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
16. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29: 1544-1549.
17. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992; 23: 646-652.
18. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
19. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
20. Hill MD, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Canadian Journal of Neurological Sciences 2001; 28: 232-238.
21. Schmulling S, Rudolf J, Strotmann-Tack T, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovascular Diseases 2003; 16: 183-190.
22. del Zoppo GJ, Higashida , Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11.
23. Kornowski R, Glikson M, Hasdai D, Chernine A, Ohad D, Battler A. Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits. European Heart Journal 1994; 15: 541-546.
24. Quartermain D, Li YS, Jonas S. The low molecular weight heparin enoxaparin reduces infarct size in a rat model of temporary focal ischemia. Cerebrovascular Diseases 2003; 16: 346-355.
25. Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994; 25: 1847-1853; discussion 1853-1854.
26. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke 2004; 35: 2320-2325.
27. Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005; 36: 1452-1456.